Over the latest trailing 12-month period, total return cagr is +19.85%. The comparable SPY value is +22.51%. Year-to-date total return is +9.87%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Total Return CAGR averages 5.65% over 3 years and -3.36% over 5 years; the trailing 12 months came in at +19.85%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Edwards Lifesciences Corporation (EW)
Total Return growth vs the same quarter one year earlier, last 40 quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | +9.87% |
| 2025 | +15.16% |
| 2024 | -2.91% |
| 2023 | +2.20% |
| 2022 | -42.41% |
| 2021 | +42.00% |
| 2020 | +17.32% |
| 2019 | +52.31% |
| 2018 | +35.90% |
| 2017 | +20.29% |
| 2016 | +18.64% |
| 2015 | +24.01% |
| 2014 | +93.70% |
| 2013 | -27.07% |
| 2012 | +27.54% |
| 2011 | -12.54% |
| 2010 | +86.16% |
| 2009 | +58.05% |
| 2008 | +19.48% |
| 2007 | -2.23% |
| 2006 | +13.05% |
| 2005 | +0.85% |
| 2004 | +37.17% |
| 2003 | +18.10% |
| 2002 | -7.82% |
| 2001 | +55.66% |
| Quarter | QoQ | YoY |
|---|---|---|
| Q3 2026 (QTD) | +3.2% | +25.4% |
| Q2 2026 | +10.6% | +17.9% |
| Q1 2026 | -4.8% | +15.2% |
| Q4 2025 | +15.5% | +16.5% |
| Q3 2025 | -3.0% | +11.7% |
| Q2 2025 | +8.0% | -15.3% |
| Q1 2025 | -3.8% | -24.8% |
| Q4 2024 | +10.8% | -2.9% |
| Q3 2024 | -26.5% | -3.5% |
| Q2 2024 | -4.0% | -3.6% |
| Q1 2024 | +24.2% | +16.1% |
| Q4 2023 | +10.1% | +4.3% |
| Q3 2023 | -26.6% | -17.8% |
| Q2 2023 | +15.6% | -1.8% |
| Q1 2023 | +11.6% | -30.1% |
| Q4 2022 | -13.2% | -43.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier. The newest quarter is in progress (quarter-to-date).
